Advertisement

Platelet-Derived Microparticles: A New Index of Monitoring Platelet Activation and Inflammation in Kawasaki Disease

  • Jing Jin
  • Jing Wang
  • Yadong Lu
  • Zhidan Fan
  • Na Huang
  • Le Ma
  • Haiguo Yu
Original Article
  • 91 Downloads

Abstract

Objective

To investigate the dynamic changes of platelet-derived microparticles (PDMP) in Kawasaki disease (KD) and its clinical significance and to study its relationship with intravenous immunoglobulin (IVIG) resistance, inflammatory indicators and aspirin treatment in children with KD.

Methods

Twenty children with KD were enrolled as the experimental group, while 20 age- and gender-matched children with common febrile disease were included in the control group. Blood samples were drawn before and 7–10 d after IVIG infusion and thereafter at 1, 2, and 3 mo after the onset of KD to estimate the PDMP concentrations by enzyme linked immunosorbent assay (ELISA). C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), procalcitonin (PCT), and cytokines [Interleukin-6 (IL-6), Tumor necrosis factor-α (TNF-α), and Soluble interleukin-2 (sIL-2R)] were also measured.

Results

The level of PDMP in KD children before IVIG was significantly higher than that in controls (P < 0.0001). The PDMP level in KD children decreased significantly at 7 to 10 d after IVIG (P < 0.0001) and then decreased to the lowest level in the course of 1 to 2 mo. Some children’s PDMP level rebounded in the course of 3 mo (P = 0.047). In addition, the mean level of PDMP in IVIG-resistant children was higher than that in IVIG-effective children; however, there was no significant difference between the two groups (P = 0.1945). Furthermore, PDMP was positively correlated with hs-CRP, IL-6, and sIL-2R levels, but no correlation was observed with ESR, PCT, and TNF-α levels.

Conclusions

PDMP can be used as an index to monitor inflammation in children at the acute stage of KD. And the duration of platelet activation in KD is individualized.

Keywords

Platelet-derived microparticle Platelet activation Kawasaki disease Inflammation 

Notes

Acknowledgments

The authors are grateful to the participants and their parents for their commitment to this project. This study utilized clinical research facilities and resources provided by the Institute of Pediatrics in Children’s Hospital of Nanjing Medical University.

Contributions

HY: Principal investigator of the project. Responsible for planning out the trial, obtaining funds, and overall conduct of the trial. He takes full responsibility for the data and their accuracy and the conduct of the research. JJ: She is responsible for performing the experiment and major proportion of writing the article. JW: Responsible for the generation of data analysis and writing of results in this article. YL: He is also responsible for performing the experiment and major proportion of writing the article. NH: She is responsible for selection of subjects and collection of blood samples. ZF: Responsible for treatment of samples. LM: Responsible for communication with parents and application for Institutional Ethics Committee. HY will act as guarantor for this paper.

Compliance with Ethical Standards

Ethical Statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of Interest

None.

References

  1. 1.
    Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti-Infect Ther. 2010;8:197–203.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clin Exp Immunol. 2011;164:20–2.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lin YJ, Chang JS, Liu X, et al. Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in Kawasaki disease in Han Chinese in Taiwan. Sci Rep. 2015;5:14762.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Li JS, Newburger JW. Antiplatelet therapy in pediatric cardiovascular patients. Pediatr Cardiol. 2010;31:454–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Tamir A, Sorrentino S, Motahedeh S, et al. The macromolecular architecture of platelet-derived microparticles. J Struct Biol. 2016;193:181–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Italiano JJ, Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol. 2010;17:578–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol. 2004;124:376–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48:180–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211–7.CrossRefPubMedGoogle Scholar
  11. 11.
    van der Zee PM, Biro E, Ko Y, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006;52:657–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Diehl P, Nagy F, Sossong V, et al. Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost. 2008;99:711–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Burbano C, Rojas M, Vasquez G, et al. Microparticles that form immune complexes as modulatory structures in autoimmune responses. Mediat Inflamm. 2015;2015:267590.CrossRefGoogle Scholar
  14. 14.
    Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100:1084–8.CrossRefPubMedGoogle Scholar
  15. 15.
    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.Google Scholar
  16. 16.
    Li ZY, Lou JG, Chen J. Analysis of primary symptoms and disease spectrum in Epstein-Barr virus infected children. Zhonghua Er Ke Za Zhi. 2004;42:20–2.PubMedGoogle Scholar
  17. 17.
    Chandrashekar L, Rajappa M, Revathy G, et al. Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin Chim Acta. 2015;446:181–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Hsu J, Gu Y, Tan SL, Narula S, DeMartino JA, Liao C. Bruton's tyrosine kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol Lett. 2013;150:97–104.CrossRefPubMedGoogle Scholar
  19. 19.
    Hayon Y, Dashevsky O, Shai E, Brill A, Varon D, R. Leker R. Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. Curr Neurovasc Res. 2012;9:185–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;113:3365–74.PubMedGoogle Scholar
  21. 21.
    Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009;113:1112–21.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Smalley DM, Root KE, Cho H, Ross MM, Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost. 2007;97:67–80.PubMedGoogle Scholar
  23. 23.
    Dean WL, Lee MJ, Cummins TD, Schultz DJ, Powell DW. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost. 2009;102:711–8.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97:425–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM. Microparticles: biomarkers and beyond. Clin Sci (Lond). 2013;124:423–41.CrossRefGoogle Scholar
  26. 26.
    Drutskaya MS, Efimov GA, Kruglov AA, Nedospasov SA. Can we design a better anti-cytokine therapy? J Leukoc Biol. 2017;102:783–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Larsen SB, Grove EL, Wurtz M, et al. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost. 2015;114:519–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim HJ, Choi EH, Lim YJ, Kil HR. The usefulness of platelet-derived microparticle as biomarker of antiplatelet therapy in Kawasaki disease. J Korean Med Sci. 2017;32:1147–53.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kimura M, Harazaki M, Fukuoka T, et al. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. Pediatr Int. 2017;59:397–403.CrossRefPubMedGoogle Scholar
  30. 30.
    Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean J Pediatr. 2016;59:477–82.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Seki M, Kobayashi T, Kobayashi T, et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30:145–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J. 2014;78:188–93.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  1. 1.Children’s Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Nanjing Tongren HospitalSchool of Medicine Southeast UniversityNanjingChina

Personalised recommendations